These discoveries provide guidance for precision radiotherapy in prostate cancer: PARP1-EJ repair switching can serve as a criterion for patient selection, while effectively inducing tumor cell senescence is a key mechanism for successful treatment. This evidence concerns the gene PARP1 and prostate cancer.